Therapeutic Area

Uncontrolled inflammation that causes tissue damage has driven the need for targeted immuno-modulators. There are multiple players in the inflammatory processes that can be modelled in vitro including standard cytokine release and inflammasome assays or more customised multicellular assays. Chronic inflammation associated with aging “Inflammaging” is an increasing focus of therapeutic intervention.

• Can you test both acute and chronic inflammatory responses? 

Yes, we offer in vitro inflammation assays to test both acute (neutrophil activation, monocyte cytokine release) and chronic inflammation (macrophage, fibroblast and epithelial interactions). 

• Do you offer assays to assess inflammasome activation? 

Yes, we offer NLRP3 inflammasome assays to study chronic inflammatory diseases such as such as arthritis, Alzheimer’s disease and inflammatory bowel disease. Inflammasome activation is driven using a variety of TLR and DAMPs signals; IL-1b and IL-18 is controlled using NLRP3 inhibitors. 

• Can you evaluate whether a drug candidate will drive cytokine release syndrome? 

Yes, we offer cytokine release assays (CRA) to evaluate the potential risk of novel biologics or cellular therapies to drive cytokine release syndrome. These assays are performed using both healthy and disease-derived immune cells to assess safety in early drug development and to support IND-submissions.

Our tailored approach to assay design and execution provides precise solutions for novel therapeutics, ensuring the success of your drug development programme. Visit our testimonial page to read how our immunology CRO services and collaborative efforts have helped our partners achieve quality outcomes to their immunology-focused enquiries.